With the past preclinical evidence and ongoing clinical trials, we also provide an overview of the history and current landscape of DDR inhibitors in cancer treatment, with especial focus on the combination of DDR‐targeted therapies with other cancer treatment strategies. This evidence concerns the gene DDR1 and cancer.